GLTO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases...

Stats
Šios dienos apimtis	277 477
Vidutinė apimtis	211 673
Rinkos kapitalizacija	19.44M
EPS	$0 ( 2024-04-26 )
Kita pelno data	( $-0.410 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.500
ATR14	$0.00400 (0.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Schambye Hans T.	Buy	200 000	Restricted Stock Units
2024-01-03	Winslow Garrett	Buy	100 000	Restricted Stock Units
2024-01-03	Freve Jonathan	Buy	100 000	Restricted Stock Units
2023-08-15	Orbimed Advisors Llc	Sell	535 534	Common Stock
2023-08-15	Orbimed Advisors Llc	Sell	248 819	Common Stock

INSIDER POWER
-13.29
Last 96 transactions
Buy: 4 275 597 \| Sell: 1 504 628

Tūris Koreliacija

Ilgas: 0.17 (neutral)

Trumpas: 0.42 (neutral)

Signal:(52.181) Neutral

Galecto, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Galecto, Inc. Koreliacija - Valiuta/Žaliavos

-0.68
( moderate negative )

-0.65
( moderate negative )

0.00
( neutral )

-0.78
( moderate negative )

0.69
( moderate )

0.52
( weak )

Galecto, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-830 000 (0.00 %)
EPS:	$-1.440

FY	2023
Pajamos:	$0
Bruto pelnas:	$-830 000 (0.00 %)
EPS:	$-1.440

FY	2022
Pajamos:	$0
Bruto pelnas:	$-490 000 (0.00 %)
EPS:	$-2.44

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.05

Financial Reports:

No articles found.

Galecto, Inc.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.